

Title (en)
PHARMACEUTICAL COMPOSITION OF NATEGLINIDE AND ANOTHER ANTIDIABETIC AGENT

Title (de)
ZUSAMMENSETZUNG WELCHE NATEGLINIDE UND EINE ANDERE ANTIDIABETISCHE VERBINDUNG ENTHÄLT

Title (fr)
COMPOSITION PHARMACEUTIQUE CONTENANT NATEGLINIDE ET UN AUTRE AGENT ANTIDIABETIQUE

Publication
EP 1212077 A2 20020612 (EN)

Application
EP 00969260 A 20000915

Priority
• EP 0009074 W 20000915
• GB 0021055 A 20000826
• US 39836499 A 19990917
• US 54548000 A 20000407

Abstract (en)
[origin: EP2011507A2] The invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, which comprises nateglinide (I) or repaglinide and at least one other antidiabetic compound selected from the group consisting of thiazolidinedione derivatives (glitazones), sulfonyl urea derivatives and metformin for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of diseases, especially metabolic disorders and in particular type 2 diabetes and diseases and conditions associated with diabetes; to a composition, respectively, which comprises nateglinide and a pharmaceutically acceptable carrier and to a process of making such composition; the use of such combination or composition for the preparation of a medicament for the prevention, delay of progression or treatment of metabolic disorders; a method of prevention, delay of progression or treatment of diseases in warm-blooded animals; the use of such combination or composition for the cosmetic treatment of a mammal in order to effect a cosmetically beneficial loss of body weight; and to a method of improving the bodily appearance of a warm-blooded animal.

IPC 1-7
A61P 3/10; A61K 31/428; A61K 31/198

IPC 8 full level
A61K 9/20 (2006.01); **A61K 9/48** (2006.01); **A61K 31/195** (2006.01); **A61K 9/16** (2006.01); **A61K 31/198** (2006.01); **A61K 31/425** (2006.01); **A61K 31/426** (2006.01); **A61K 31/44** (2006.01); **A61K 31/4433** (2006.01); **A61K 31/4439** (2006.01); **A61K 31/63** (2006.01); **A61K 31/64** (2006.01); **A61K 38/28** (2006.01); **A61K 47/04** (2006.01); **A61K 47/12** (2006.01); **A61K 47/26** (2006.01); **A61K 47/32** (2006.01); **A61K 47/38** (2006.01); **A61P 1/00** (2006.01); **A61P 1/04** (2006.01); **A61P 3/00** (2006.01); **A61P 3/04** (2006.01); **A61P 3/10** (2006.01); **A61P 9/00** (2006.01); **A61P 9/10** (2006.01); **A61P 9/12** (2006.01); **A61P 13/12** (2006.01); **A61P 15/00** (2006.01); **A61P 15/10** (2006.01); **A61P 17/00** (2006.01); **A61P 19/02** (2006.01); **A61P 19/10** (2006.01); **A61P 27/06** (2006.01); **A61P 27/12** (2006.01)

CPC (source: EP FI KR)
A61K 9/16 (2013.01 - FI); **A61K 9/20** (2013.01 - FI); **A61K 9/2054** (2013.01 - EP); **A61K 9/48** (2013.01 - FI); **A61K 31/195** (2013.01 - EP); **A61K 31/198** (2013.01 - EP FI); **A61K 31/425** (2013.01 - EP); **A61K 31/44** (2013.01 - EP); **A61K 31/64** (2013.01 - EP KR); **A61P 1/00** (2018.01 - EP); **A61P 1/04** (2018.01 - EP); **A61P 3/00** (2018.01 - EP); **A61P 3/04** (2018.01 - EP); **A61P 3/10** (2018.01 - EP); **A61P 9/00** (2018.01 - EP); **A61P 9/10** (2018.01 - EP); **A61P 9/12** (2018.01 - EP); **A61P 13/12** (2018.01 - EP); **A61P 15/00** (2018.01 - EP); **A61P 15/10** (2018.01 - EP); **A61P 17/00** (2018.01 - EP); **A61P 19/02** (2018.01 - EP); **A61P 19/10** (2018.01 - EP); **A61P 27/06** (2018.01 - EP); **A61P 27/12** (2018.01 - EP); **A61K 9/2077** (2013.01 - EP)

C-Set (source: EP)
1. **A61K 31/64 + A61K 31/195**
2. **A61K 31/44 + A61K 31/195**
3. **A61K 31/425 + A61K 31/195**
4. **A61K 31/195 + A61K 31/155**
5. **A61K 31/195 + A61K 2300/00**
6. **A61K 31/198 + A61K 2300/00**
7. **A61K 31/425 + A61K 2300/00**
8. **A61K 31/44 + A61K 2300/00**
9. **A61K 31/64 + A61K 2300/00**

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
EP 2011507 A2 20090107; AR 028299 A1 20030507; AR 028504 A2 20030514; AR 072329 A2 20100825; AU 7904400 A 20010424; BE 1013726 A5 20020702; BR 0014525 A 20020611; CA 2381992 A1 20010329; CA 2381992 C 20110329; CN 1309380 C 20070411; CN 1635874 A 20050706; CO 5200844 A1 20020927; CZ 20011723 A3 20010815; EP 1212077 A2 20020612; FI 20010683 A 20010402; FR 2798592 A1 20010323; FR 2798592 B1 20070420; HK 1046101 A1 20021227; HU P0400932 A2 20040728; HU P0400932 A3 20071128; IL 148168 A0 20020912; JP 2003509457 A 20030311; JP 2006335767 A 20061214; KR 100506428 B1 20050805; KR 100544244 B1 20060123; KR 20020038758 A 20020523; KR 20040075935 A 20040830; MY 131810 A 20070928; MY 143051 A 20110228; NO 20021197 D0 20020311; NO 20021197 L 20020516; NZ 517280 A 20040227; NZ 528738 A 20050527; PE 20010739 A1 20010713; PL 354168 A1 20031229; SG 127714 A1 20061229; SK 3602002 A3 20020702; TW 200401631 A 20040201; TW I278311 B 20070411; TW I278312 B 20070411; WO 0121159 A2 20010329; WO 0121159 A3 20011227

DOCDB simple family (application)
EP 08167253 A 20000915; AR P000104821 A 20000914; AR P010100516 A 20010205; AR P090102868 A 20090728; AU 7904400 A 20000915; BE 200000585 A 20000915; BR 0014525 A 20000915; CA 2381992 A 20000915; CN 00801976 A 20000915; CO 00069666 A 20000914; CZ 20011723 A 20000915; EP 0009074 W 20000915; EP 00969260 A 20000915; FI 20010683 A 20010402; FR 0011782 A 20000915; HK 02107767 A 20021025; HU P0400932 A 20000915; IL 14816800 A 20000915; JP 2001524585 A 20000915; JP 2006241423 A 20060906; KR 20027003551 A 20020316; KR 20047010952 A 20000915; MY PI20004314 A 20000915; MY PI20050152 A 20000915;

NO 20021197 A 20020311; NZ 51728000 A 20000915; NZ 52873800 A 20000915; PE 0009552000 A 20000915; PL 35416800 A 20000915;
SG 200401291 A 20000915; SK 3602002 A 20000915; TW 89118960 A 20000915; TW 92125226 A 20000915